They showed that the PI3K/mTOR inhibitor BEZ235 in combination with the MEK inhibitor PD0325901 decreased neurotensin peptide release, suggesting a potential benefit of PI3K/mTOR/MEK inhibitors in the treatment of patients with NETs and CS. Here, NTS is linked to Cowden syndrome 1.